Sucampo Pharmaceuticals, Inc., (Sucampo Pharmaceuticals) today announced that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration to seek market approval of a lower strength of lubiprostone (8 mcg) to treat irritable bowel syndrome with constipation (IBS-C).
A clinical trial including 50 medical centers and 304 patients has confirmed that polyethylene (PEG) laxative is safe for patients suffering from chronic constipation. The study, published in The American Journal of Gastroenterology, indicates that even elderly patients can use the drug safely for up to six months.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD) announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for doripenem, an investigational carbapenem antibiotic for the treatment of nosocomial pneumonia, a pneumonia that is acquired in a hospital or other healthcare setting.
Lubiprostone is a novel therapy indicated for treatment of chronic idiopathic constipation in adults.
Researchers are continually looking for unique pathways to treat digestive diseases, such as constipation and irritable bowel syndrome.
Three new therapy options, including two novel medications, showed promise in the treatment of irritable bowel syndrome (IBS), according to research presented at Digestive Disease Week 2007 (DDW).
In patients with idiopathic constipation, which occurs with no identifiable cause, in whom conservative treatment has failed, surgical procedures (e.g., colectomy) are associated with a high failure rate and substantial morbidity.
A new study demonstrated that the active ingredient in AMITIZA? (lubiprostone), given 8 mcg twice a day, may improve symptom relief rates in adults with irritable bowel syndrome with constipation (IBS-C).
Of the 57 million people dying worldwide each year, 6 million deaths are caused by cancer and 3 million from HIV/AIDS, with the majority of both occurring in developing countries. These figures indicate the large number of people experiencing incapacitation and pain through shortness of breath, constipation, diarrhoea, nausea as well as distress, depression and anxiety.
Data from a pooled analysis of three studies suggest that in patients with pain caused by diabetic nerve damage, or diabetic peripheral neuropathy, who are treated with Cymbalta (duloxetine HCl), improvements in both average daily pain and night pain severity were associated with less pain-related sleep interference than in those patients taking sugar pill.